---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-121674"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:05:12.634326+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Humacyte enters $60M at-the-market equity offering with TD Cowen

## Summary
- Up to $60M in common stock may be sold from time to time through TD Securities (USA) LLC as agent.
- TD Cowen will receive a commission of up to 3.0% of gross proceeds.
- Net proceeds to fund commercialization of Symvess in vascular trauma, pipeline, and working capital.
- Company is not obligated to sell any shares; ATM allows sales at prevailing market prices.

## SEC filing metadata
- accession: 0001104659-25-121674
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465925121674/0001104659-25-121674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465925121674/tm2533475d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-121674
- JSON: https://secwatch.observer/filing/0001104659-25-121674.json
- Plain text: https://secwatch.observer/filing/0001104659-25-121674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.